NCT04658147
Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma
StatusActive, Not Recruiting
PhasePhase 1
Primary completion
At risk: Primary endpoint(s) modified.
See at-risk trials from Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 21 versions: 13 with changes below, 8 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Results posted: Oct 28, 2026 Show 4 more changesShow less
- Primary endpoint(s) modified
- Eligibility criteria expanded, about 33 words
- Secondary endpoints: 12 to 14
- Study title shortened, about 6 words
- Minor Primary completion date changed from estimate of Dec 1, 2025 to Sep 2, 2025
- Study completion date: Dec 1, 2026 to Jun 1, 2030
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 20 to confirmed 31
- Site details revised at 2 of 2 sites
- Notable Primary completion date: Jun 1, 2025 to Dec 1, 2025
- Study completion date: Jun 1, 2026 to Dec 1, 2026
- Minor Study sites: 1 to 2v14
Show 7 earlier versionsHide 7 earlier versions
- Minor Site contact updatedv10
- Minor Start date changed from estimate of Jun 2021 to May 28, 2021
- Site contact updated
- Minor Primary completion date: Jun 2025 to Jun 1, 2025
- Study completion date: Jun 2025 to Jun 1, 2026
- Notable Trial status: Not Yet Recruiting to Recruiting
- Site details revised
- Notable Start date: Apr 2021 to Jun 2021
- Primary and study completion dates: Apr 2025 to Jun 2025
- Notable Start date: Feb 2021 to Apr 2021
- Primary completion date: Feb 2025 to Apr 2025
- Study completion date: Feb 2026 to Apr 2025
- Minor Study title shortened, about 1 wordv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Number of Patients Precluded From Surgery
Timeframe: Up to 2 months
Secondary (14)
Number of Participants Experiencing Grade 3 or Above Study Drug-related Adverse Event (AE)
Number of Participants Who Obtain R0 Resection
Number of Evaluable Patients With Pathologic Response to Treatment
Objective Response Rate (ORR) at 8 Weeks Using Response Evaluation Criteria for Solid Tumors (RECIST 1.1).
Overall Survival (OS) Rate at 12 Months
Show 9 moreShow less
Overall Survival (OS) Rate at 18 Months
Overall Survival (OS) at 3 Years
Overall Survival (OS) at 5 Years
Disease Free Survival (DFS) Rate at 12 Months
Disease Free Survival (DFS) at 18 Months
Disease Free Survival (DFS) at 3 Years
Disease Free Survival (DFS) at 5 Years
Overall Survival (OS)
Disease Free Survival (DFS)
Arms and interventions
Arm A - NivolumabExperimental
Participants receive Nivolumab only.
Arm B - Nivolumab and RelatlimabExperimental
Participants receive Nivolumab and Relatlimab.
Drugs: Nivolumab, Relatlimab
Sites
2 sites in 1 country